Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs FTAI Aviation Ltd (FTAI) Price & Performance

AbCellera Biologics IncTrade
FTAI Aviation LtdTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs FTAI Aviation Ltd — how do they compare? AbCellera Biologics Inc trades at $8.94 (market cap $2.85B), while FTAI Aviation Ltd trades at $225.49 (market cap $22.08B). The key difference: FTAI Aviation Ltd is far larger — about 7.7× AbCellera Biologics Inc's market cap, and FTAI Aviation Ltd pays a 0.93% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLFTAI
Market Cap
$2.85B$22.08B
Sector
HealthIndustrials
52-Week High
$9.76$310.04
52-Week Low
$2.78$140.40
Enterprise Value
$2.45B$25.20B
Dividend Yield
0.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

FTAI Aviation Ltd

FTAI Aviation trades at $216.24, down 2.26% for the day, with a bearish technical signal and recent earnings misses. The company reported strong revenue growth to $2.51B in 2025 but faces margin compression, with net income margin declining to 15.94% in 2026. Recent news highlights strategic collaborations and a major power systems order, while analyst consensus remains unanimously bullish with a $341.67 price target.

The outlook is mixed: robust analyst support and growth initiatives in power and MRO segments offer upside, but high valuations (P/E 46.94), earnings misses, and negative operating cash flows pose risks. Investors should weigh long-term growth potential against near-term execution challenges and market volatility.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About FTAI Aviation Ltd

FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.

Read more on FTAI